A phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors

This research study is about a medicine called asciminib, which has already been approved for treating a type of blood cancer called Chronic Myelogenous Leukemia (CML). CML is a long-term condition that affects certain cells in your bone marrow. This study is specifically for people with CML who are in the 'chronic phase' – this is the most common and usually less severe form of the disease. Importantly, this study is for patients who have already tried at least two other CML medicines, known as tyrosine kinase inhibitors (TKIs), but these treatments haven't been as effective as doctors would like. This means the study is looking at optimising treatment for people who might be running out of options.

The main purpose of this study is to learn more about the best way to use asciminib in these specific patients. Researchers want to see if changing how asciminib is given can lead to better control of the CML. The main thing they will measure is how many people achieve something called a 'Major Molecular Response' (MMR) after about a year (48 weeks) of treatment. MMR is a way doctors measure how much the cancer-causing cells in your body have reduced. Achieving MMR is a good sign that the treatment is working well.

Beyond checking how well the treatment controls the cancer, the study will also pay close attention to safety. Researchers will carefully track any side effects, how often they occur, and if they are mild, moderate, or severe. They will also look at changes in your blood test results, heart activity (using an ECG), and other general health checks like blood pressure and physical exams. This all helps to make sure the medicine is not only effective but also safe for patients.